SG10201913796UA - Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide - Google Patents

Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Info

Publication number: SG10201913796UA
Authority: SG; Singapore
Prior art keywords: ynoyl; pyrazin; imidazo; pyrrolidin; benzamide
Prior art date: 2015-07-02

Application number

SG10201913796UA

Other languages

English (en)

Inventor

Fritz Blatter

Tim Ingallinera

Tjeerd Barf

Edwin Aret

Cecile Krejsa

Jerry Evarts

Original Assignee

Acerta Pharma Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-02

Filing date

2016-07-01

Publication date

2020-03-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56363881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201913796U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-07-01 Application filed by Acerta Pharma Bv filed Critical Acerta Pharma Bv

2020-03-30 Publication of SG10201913796UA publication Critical patent/SG10201913796UA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Inorganic Chemistry (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Neurology (AREA)
AIDS & HIV (AREA)
Vascular Medicine (AREA)

SG10201913796UA 2015-07-02 2016-07-01 Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide SG10201913796UA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562188468P	2015-07-02	2015-07-02
US201562271708P	2015-12-28	2015-12-28

Publications (1)

Publication Number	Publication Date
SG10201913796UA true SG10201913796UA (en)	2020-03-30

Family

ID=56363881

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10201913796UA SG10201913796UA (en)	2015-07-02	2016-07-01	Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Country Status (30)

Country	Link
US (7)	US9796721B2 (fr)
EP (4)	EP3954690B1 (fr)
JP (3)	JP6829215B2 (fr)
KR (2)	KR102688052B1 (fr)
CN (2)	CN108349978B (fr)
AU (3)	AU2016286548B2 (fr)
CA (1)	CA2991096A1 (fr)
CL (1)	CL2017003445A1 (fr)
CY (3)	CY1124519T1 (fr)
DK (3)	DK3613745T3 (fr)
ES (3)	ES2946489T3 (fr)
FI (1)	FI3954690T3 (fr)
HK (1)	HK1250511A1 (fr)
HR (3)	HRP20230417T1 (fr)
HU (3)	HUE062258T2 (fr)
IL (3)	IL293821A (fr)
LT (3)	LT3317281T (fr)
MA (1)	MA50817B1 (fr)
MD (1)	MD3317281T2 (fr)
MX (2)	MX2020014163A (fr)
MY (1)	MY193514A (fr)
PL (3)	PL3954690T3 (fr)
PT (3)	PT3613745T (fr)
RS (3)	RS60411B1 (fr)
RU (1)	RU2018103913A (fr)
SG (1)	SG10201913796UA (fr)
SI (3)	SI3613745T1 (fr)
SM (3)	SMT202100597T1 (fr)
WO (1)	WO2017002095A1 (fr)
ZA (2)	ZA201800329B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SMT202100674T1 (it) *	2014-08-11	2022-01-10	Acerta Pharma Bv	Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
PL3954690T3 (pl)	2015-07-02	2023-08-14	Acerta Pharma B.V.	Postacie stałe i formulacje (s)-4-(8-amino-3-(1-(but-2-ynoilo)pirolidyn-2-ylo)imidazo[1,5-a]-pirazyn-1-ylo)-n-(pirydyn-2-ylo)benzamidu
CN113416194A (zh)	2016-10-05	2021-09-21	杭州领业医药科技有限公司	Acp-196的晶型及其制备方法和药物组合物
WO2018115965A1 (fr) *	2016-12-23	2018-06-28	Acerta Pharma Bv	Formes solides de composés d'imidazopyrazine
WO2018148961A1 (fr) *	2017-02-20	2018-08-23	杭州领业医药科技有限公司	Forme cristalline du sel acp-196, procédé de préparation, composition pharmaceutique et utilisation associés
MX2019011496A (es)	2017-03-27	2020-01-23	Tesaro Inc	Composiciones de niraparib.
SG11201908977SA (en) *	2017-03-27	2019-10-30	Tesaro Inc	Niraparib formulations
US10717740B2 (en)	2017-06-13	2020-07-21	Dr. Reddy's Laboratories Limited.	Solid forms of acalabrutinib and process for preparation thereof
WO2019041026A1 (fr) *	2017-08-29	2019-03-07	Apotex Inc.	Nouvelles formes cristallines d'acalabrutinib
MX2020003760A (es)	2017-09-26	2020-07-29	Tesaro Inc	Formulaciones de niraparib.
WO2019105359A1 (fr) *	2017-11-30	2019-06-06	苏州科睿思制药有限公司	Forme cristalline de l'acalabrutinib, son procédé de préparation et son application
CN111527089B (zh) *	2018-01-05	2021-03-12	苏州科睿思制药有限公司	Acalabrutinib的新晶型及其制备方法和用途
WO2019159097A1 (fr) *	2018-02-14	2019-08-22	Sun Pharmaceutical Industries Limited	Nouvelles formes polymorphes cristallines d'acalabrutinib
US20210087195A1 (en) *	2018-04-26	2021-03-25	Crystal Pharmaceutical (Suzhou) Co., Ltd.	New crystal form of acalbrutinib, preparation method therefor and use thereof
EP3587421A1 (fr)	2018-06-29	2020-01-01	Sandoz AG	Formes cristallines de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo [1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
AU2019332882B2 (en)	2018-08-29	2022-01-27	Acerta Pharma B.V.	Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}N-(pyridin-2-yl)-benzamide
WO2020053795A2 (fr)	2018-09-13	2020-03-19	Fresenius Kabi Oncology Ltd.	Procédé de préparation d'acalabrutinib et de ses intermédiaires
WO2020065667A1 (fr)	2018-09-25	2020-04-02	Cipla Limited	Nouveaux polymorphes d'acalabrutinib, un inhibiteur de la tyrosine kinase de bruton
EP3947386A1 (fr)	2019-03-27	2022-02-09	Assia Chemical Industries Ltd	Formes à l'état solide d'acalabrutinib
WO2020225831A1 (fr) *	2019-05-09	2020-11-12	Msn Laboratories Private Limited, R&D Center	Procédé amélioré pour la préparation de 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
WO2021135346A1 (fr) *	2019-12-31	2021-07-08	苏州科睿思制药有限公司	Nouvelle forme cristalline de l'acalabrutinib, son procédé de préparation et son utilisation
WO2021239893A1 (fr)	2020-05-29	2021-12-02	Bend Research, Inc.	Dispersion solide amorphe d'acalabrutinib
KR20230027201A (ko) *	2020-06-19	2023-02-27	아세르타 파마. 비.브이.	아칼라브루티닙 말레산염 투약 형태
CN112028896A (zh) *	2020-10-14	2020-12-04	奥锐特药业(天津)有限公司	阿卡替尼的新晶型及其制备方法
US20240315978A1 (en) *	2021-01-13	2024-09-26	Natco Pharma Limited	Pharmaceutical compositions comprising acalabrutinib
WO2023014817A1 (fr)	2021-08-03	2023-02-09	Syros Pharmaceuticals, Inc.	Compositions et méthodes pour traiter des lymphomes avec un inhibiteur de cdk7 en combinaison avec un inhibiteur de btk
WO2023205279A1 (fr) *	2022-04-19	2023-10-26	The Johns Hopkins University	Spectroscopie raman améliorée avec addition de composés aromatiques
WO2024164066A1 (fr) *	2023-02-09	2024-08-15	Apotex Inc	Formes cristallines de maléate d'acalabrutinib

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2001081031A (ja)	1999-08-30	2001-03-27	Schering Ag	溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
JP2003509427A (ja)	1999-09-17	2003-03-11	アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー	治療剤としてのキナーゼ阻害剤
US6921763B2 (en)	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
US6998391B2 (en)	2002-02-07	2006-02-14	Supergen.Inc.	Method for treating diseases associated with abnormal kinase activity
JP4916883B2 (ja)	2003-10-15	2012-04-18	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	イミダゾピラジンチロシンキナーゼ阻害剤
EP2308879A1 (fr)	2004-04-02	2011-04-13	OSI Pharmaceuticals, Inc.	Inhibiteurs hétérobicycliques de la protéine kinase à anneau bicyclique substitué en 6,6
ITMI20051231A1 (it)	2005-06-29	2006-12-30	Pharmaproducts Uk Ltd	Formulazioni farmaceutiche contenenti colostro e calcio folinato per il trattamento delle affezioni del cavo orale
CA2616416A1 (fr)	2005-09-09	2007-05-03	Labopharm, Inc.	Composition de trazodone a administration quotidienne
DE602006021608D1 (de)	2005-11-17	2011-06-09	Osi Pharm Inc	Kondensierte bicyclische mtor-inhibitoren
PE20070855A1 (es)	2005-12-02	2007-10-14	Bayer Pharmaceuticals Corp	Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
AR057960A1 (es)	2005-12-02	2007-12-26	Osi Pharm Inc	Inhibidores de proteina quinasa biciclicos
US7651687B2 (en)	2006-03-13	2010-01-26	Osi Pharmaceuticals, Inc.	Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
PT2529622T (pt)	2006-09-22	2018-04-24	Pharmacyclics Llc	Inibidores de tirosina cinase de bruton
SG10201508035TA (en)	2007-03-28	2015-10-29	Pharmacyclics Inc	Inhibitors of bruton's tyrosine kinase
US20120101114A1 (en)	2007-03-28	2012-04-26	Pharmacyclics, Inc.	Inhibitors of bruton's tyrosine kinase
US8088824B2 (en) *	2007-08-15	2012-01-03	Reata Pharmaceuticals Inc.	Forms of CDDO methyl ester
RU2010128239A (ru)	2007-12-13	2012-01-20	Новартис АГ (CH)	Комбинации терапевтических средств, предназначенных для лечения рака
US9095592B2 (en)	2008-11-07	2015-08-04	The Research Foundation For The State University Of New York	Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en)	2009-03-02	2012-10-30	Roche Palo Alto Llc	Inhibitors of Bruton's tyrosine kinase
EP2424368B1 (fr)	2009-04-29	2014-12-31	Locus Pharmaceuticals, Inc.	Composés de pyrrolotriazine
CA2787291C (fr)	2010-02-08	2016-04-19	Msd Oss B.V.	Composes de 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine
CN102190594A (zh) *	2010-03-17	2011-09-21	上海医药工业研究院	阿戈美拉汀氯化氢水合物及其制备方法
UY33288A (es)	2010-03-25	2011-10-31	Glaxosmithkline Llc	Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
ES2948312T3 (es)	2010-05-31	2023-09-08	Ono Pharmaceutical Co	Derivado de purinona como inhibidor de Btk quinasa
CA3007788C (fr)	2010-06-03	2020-03-10	Pharmacyclics Llc	Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
US20120053189A1 (en)	2010-06-28	2012-03-01	Pharmacyclics, Inc.	Btk inhibitors for the treatment of immune mediated conditions
EP2710007B1 (fr)	2011-05-17	2019-12-11	The Regents of The University of California	Inhibiteurs de kinase
MX2014000130A (es)	2011-06-28	2014-05-01	Pharmacyclics Inc	Procedimientos y composiciones para la inhibicion de resorcion osea.
EA201490265A1 (ru)	2011-07-13	2014-12-30	Фармасайкликс, Инк.	Ингибиторы тирозинкиназы брутона
EP2548877A1 (fr)	2011-07-19	2013-01-23	MSD Oss B.V.	Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
MY192354A (en) *	2011-07-19	2022-08-17	Merck Sharp & Dohme	4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
AU2012285988B2 (en)	2011-07-19	2017-05-25	Merck Sharp & Dohme B.V.	4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides Btk-inhibitors
CA3110966A1 (fr)	2011-10-19	2013-04-25	Pharmacyclics Llc	Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
US20140212425A1 (en)	2011-12-05	2014-07-31	Immunomedics, Inc.	Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US8377946B1 (en)	2011-12-30	2013-02-19	Pharmacyclics, Inc.	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
BR112014028841B1 (pt) *	2012-05-23	2021-01-12	Nerviano Medical Sciences S.R.L.	Formas cristalinas 1 e 2, composição farmacêutica, uso da forma cristalina 1 para o tratamento de um estado de doença tratável pela inibição de alk e processo para a preparação de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metilpiperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)- benzamida
EP2948458B1 (fr)	2013-01-23	2019-05-01	Merck Sharp & Dohme Corp.	Inhibiteurs de btk
CN105073115A (zh)	2013-03-14	2015-11-18	药品循环有限责任公司	布鲁顿氏酪氨酸激酶抑制剂和cyp3a4抑制剂的组合
WO2014143807A2 (fr)	2013-03-15	2014-09-18	Stromatt Scott	Anticorps anti-cd37 et polythérapie par antagoniste de la voie bcr pour le traitement de malignités b et de troubles des lymphocytes b
KR20150141971A (ko)	2013-04-08	2015-12-21	파마싸이클릭스 엘엘씨	이브루티닙 병용 요법
AP2015008750A0 (en)	2013-04-08	2015-09-30	Bayer Pharma AG	Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
WO2015018522A1 (fr)	2013-08-06	2015-02-12	Oncoethix Sa	Inhibiteur de bromodomaine bet présentant une synergie avec plusieurs agents anti-cancéreux dans des modèles cliniques de lymphome diffus de cellule b de grande taille (dlbcl)
WO2015057992A1 (fr) *	2013-10-16	2015-04-23	Izumi Raquel	Inhibiteurs btk pour la mobilisation hématopoïétique
EP3076974A1 (fr)	2013-12-05	2016-10-12	Acerta Pharma B.V.	Association thérapeutique d'un inhibiteur de pi3k et d'un inhibiteur de btk
US9556150B2 (en)	2013-12-13	2017-01-31	Hoffmann-La Roche Inc.	Inhibitors of bruton's tyrosine kinase
WO2015110923A2 (fr)	2014-01-21	2015-07-30	Acerta Pharma B.V.	Méthodes de traitement de la leucémie lymphoïde chronique et du lymphome à petits lymphocytes en utilisant un inhibiteur de btk
FR3021783B1 (fr)	2014-06-02	2016-05-13	Morpho	Procede de validation de l'authenticite d'un element du corps humain
PL3954690T3 (pl) *	2015-07-02	2023-08-14	Acerta Pharma B.V.	Postacie stałe i formulacje (s)-4-(8-amino-3-(1-(but-2-ynoilo)pirolidyn-2-ylo)imidazo[1,5-a]-pirazyn-1-ylo)-n-(pirydyn-2-ylo)benzamidu

2016
- 2016-07-01 PL PL21182842.1T patent/PL3954690T3/pl unknown
- 2016-07-01 IL IL293821A patent/IL293821A/en unknown
- 2016-07-01 RU RU2018103913A patent/RU2018103913A/ru unknown
- 2016-07-01 PL PL19196939T patent/PL3613745T3/pl unknown
- 2016-07-01 AU AU2016286548A patent/AU2016286548B2/en active Active
- 2016-07-01 SI SI201631364T patent/SI3613745T1/sl unknown
- 2016-07-01 EP EP21182842.1A patent/EP3954690B1/fr active Active
- 2016-07-01 CN CN201680050713.6A patent/CN108349978B/zh active Active
- 2016-07-01 ES ES21182842T patent/ES2946489T3/es active Active
- 2016-07-01 DK DK19196939.3T patent/DK3613745T3/da active
- 2016-07-01 ES ES16735945T patent/ES2797987T3/es active Active
- 2016-07-01 HU HUE21182842A patent/HUE062258T2/hu unknown
- 2016-07-01 US US15/200,875 patent/US9796721B2/en active Active
- 2016-07-01 EP EP19196939.3A patent/EP3613745B1/fr active Active
- 2016-07-01 SI SI201630805T patent/SI3317281T1/sl unknown
- 2016-07-01 DK DK16735945.4T patent/DK3317281T3/da active
- 2016-07-01 LT LTEP16735945.4T patent/LT3317281T/lt unknown
- 2016-07-01 RS RS20200681A patent/RS60411B1/sr unknown
- 2016-07-01 EP EP23157244.7A patent/EP4209493A1/fr active Pending
- 2016-07-01 LT LTEP19196939.3T patent/LT3613745T/lt unknown
- 2016-07-01 SM SM20210597T patent/SMT202100597T1/it unknown
- 2016-07-01 PT PT191969393T patent/PT3613745T/pt unknown
- 2016-07-01 IL IL274066A patent/IL274066B/en unknown
- 2016-07-01 RS RS20230367A patent/RS64195B1/sr unknown
- 2016-07-01 PL PL16735945T patent/PL3317281T3/pl unknown
- 2016-07-01 FI FIEP21182842.1T patent/FI3954690T3/fi active
- 2016-07-01 KR KR1020187003310A patent/KR102688052B1/ko active Active
- 2016-07-01 RS RS20211291A patent/RS62455B1/sr unknown
- 2016-07-01 MY MYPI2017001918A patent/MY193514A/en unknown
- 2016-07-01 MA MA50817A patent/MA50817B1/fr unknown
- 2016-07-01 SG SG10201913796UA patent/SG10201913796UA/en unknown
- 2016-07-01 HR HRP20230417TT patent/HRP20230417T1/hr unknown
- 2016-07-01 MX MX2020014163A patent/MX2020014163A/es unknown
- 2016-07-01 LT LTEP21182842.1T patent/LT3954690T/lt unknown
- 2016-07-01 SI SI201631705T patent/SI3954690T1/sl unknown
- 2016-07-01 MD MDE20180479T patent/MD3317281T2/ro unknown
- 2016-07-01 HU HUE19196939A patent/HUE056008T2/hu unknown
- 2016-07-01 SM SM20200304T patent/SMT202000304T1/it unknown
- 2016-07-01 CN CN202110761102.5A patent/CN113480542A/zh active Pending
- 2016-07-01 HU HUE16735945A patent/HUE049989T2/hu unknown
- 2016-07-01 EP EP16735945.4A patent/EP3317281B1/fr active Active
- 2016-07-01 MX MX2018000179A patent/MX378495B/es unknown
- 2016-07-01 KR KR1020247024480A patent/KR20240115937A/ko active Pending
- 2016-07-01 HR HRP20211511TT patent/HRP20211511T1/hr unknown
- 2016-07-01 WO PCT/IB2016/053988 patent/WO2017002095A1/fr active Application Filing
- 2016-07-01 JP JP2017568182A patent/JP6829215B2/ja active Active
- 2016-07-01 SM SM20230165T patent/SMT202300165T1/it unknown
- 2016-07-01 ES ES19196939T patent/ES2895802T3/es active Active
- 2016-07-01 PT PT211828421T patent/PT3954690T/pt unknown
- 2016-07-01 DK DK21182842.1T patent/DK3954690T3/da active
- 2016-07-01 PT PT167359454T patent/PT3317281T/pt unknown
- 2016-07-01 CA CA2991096A patent/CA2991096A1/fr active Pending
2017
- 2017-09-18 US US15/707,508 patent/US10167291B2/en active Active
- 2017-12-28 CL CL2017003445A patent/CL2017003445A1/es unknown
- 2017-12-28 IL IL256633A patent/IL256633B/en active IP Right Grant
2018
- 2018-01-17 ZA ZA2018/00329A patent/ZA201800329B/en unknown
- 2018-07-31 HK HK18109886.8A patent/HK1250511A1/zh unknown
- 2018-11-01 US US16/177,927 patent/US10640509B2/en active Active
2020
- 2020-01-16 ZA ZA2020/00300A patent/ZA202000300B/en unknown
- 2020-04-30 US US16/863,033 patent/US11059829B2/en active Active
- 2020-06-10 HR HRP20200934TT patent/HRP20200934T1/hr unknown
- 2020-07-02 CY CY20201100611T patent/CY1124519T1/el unknown
- 2020-11-24 AU AU2020277123A patent/AU2020277123B2/en active Active
2021
- 2021-01-21 JP JP2021007689A patent/JP7091494B2/ja active Active
- 2021-06-10 US US17/344,233 patent/US20220177476A1/en not_active Abandoned
- 2021-10-19 CY CY20211100904T patent/CY1124815T1/el unknown
2022
- 2022-01-27 US US17/586,726 patent/US11820777B2/en active Active
- 2022-06-15 JP JP2022096907A patent/JP2022120156A/ja active Pending
- 2022-12-23 AU AU2022291635A patent/AU2022291635B2/en active Active
2023
- 2023-06-01 CY CY20231100260T patent/CY1126103T1/el unknown
- 2023-10-16 US US18/487,254 patent/US20240199622A1/en active Pending

Also Published As

Publication number	Publication date
US11820777B2 (en)	2023-11-21
PT3317281T (pt)	2020-06-18
EP3954690B1 (fr)	2023-04-05
HUE049989T2 (hu)	2020-11-30
HRP20200934T1 (hr)	2020-09-18
KR102688052B1 (ko)	2024-07-25
SMT202000304T1 (it)	2020-07-08
HUE062258T2 (hu)	2023-10-28
MX2018000179A (es)	2018-06-27
ES2946489T3 (es)	2023-07-19
CN108349978B (zh)	2021-07-23
JP2021073235A (ja)	2021-05-13
RS62455B1 (sr)	2021-11-30
KR20180048593A (ko)	2018-05-10
IL293821A (en)	2022-08-01
AU2016286548B2 (en)	2020-12-10
SMT202100597T1 (it)	2021-11-12
AU2016286548A1 (en)	2018-02-01
US20180208596A1 (en)	2018-07-26
US10167291B2 (en)	2019-01-01
US20220348582A1 (en)	2022-11-03
WO2017002095A1 (fr)	2017-01-05
MA50817B1 (fr)	2021-10-29
PL3317281T3 (pl)	2020-11-02
JP2018522877A (ja)	2018-08-16
PT3613745T (pt)	2021-10-14
SI3317281T1 (sl)	2020-08-31
PL3613745T3 (pl)	2022-01-31
US20220177476A1 (en)	2022-06-09
HRP20230417T1 (hr)	2023-07-07
MY193514A (en)	2022-10-17
AU2020277123B2 (en)	2022-09-29
EP3317281B1 (fr)	2020-04-22
CA2991096A1 (fr)	2017-01-05
IL274066B (en)	2022-07-01
DK3317281T3 (da)	2020-06-15
RS60411B1 (sr)	2020-07-31
SI3613745T1 (sl)	2021-12-31
AU2020277123A1 (en)	2020-12-24
US20190337949A1 (en)	2019-11-07
SI3954690T1 (sl)	2023-07-31
KR20240115937A (ko)	2024-07-26
RU2018103913A3 (fr)	2019-12-31
ES2895802T3 (es)	2022-02-22
LT3613745T (lt)	2021-10-11
CN113480542A (zh)	2021-10-08
CY1124815T1 (el)	2022-11-25
JP2022120156A (ja)	2022-08-17
LT3317281T (lt)	2020-07-27
RU2018103913A (ru)	2019-08-02
US20200255437A1 (en)	2020-08-13
MD3317281T2 (ro)	2020-07-31
EP3317281A1 (fr)	2018-05-09
DK3954690T3 (da)	2023-06-06
HUE056008T2 (hu)	2022-01-28
SMT202300165T1 (it)	2023-07-20
MA50817A (fr)	2021-04-21
DK3613745T3 (da)	2021-10-18
US9796721B2 (en)	2017-10-24
US20170029428A1 (en)	2017-02-02
LT3954690T (lt)	2023-05-25
ES2797987T3 (es)	2020-12-04
JP7091494B2 (ja)	2022-06-27
MX378495B (es)	2025-03-11
HK1250511A1 (zh)	2018-12-21
CY1124519T1 (el)	2022-03-24
MX2020014163A (es)	2022-09-29
US10640509B2 (en)	2020-05-05
EP4209493A1 (fr)	2023-07-12
ZA202000300B (en)	2022-03-30
US20240199622A1 (en)	2024-06-20
IL256633A (en)	2018-02-28
FI3954690T3 (fi)	2023-05-31
ZA201800329B (en)	2022-04-28
AU2022291635B2 (en)	2024-06-27
PL3954690T3 (pl)	2023-08-14
EP3613745A1 (fr)	2020-02-26
CL2017003445A1 (es)	2018-05-11
IL256633B (en)	2020-05-31
JP6829215B2 (ja)	2021-02-10
US11059829B2 (en)	2021-07-13
PT3954690T (pt)	2023-06-06
HRP20211511T1 (hr)	2021-12-24
RS64195B1 (sr)	2023-06-30
IL274066A (en)	2020-06-30
AU2022291635A1 (en)	2023-02-02
EP3954690A1 (fr)	2022-02-16
CY1126103T1 (el)	2023-11-15
EP3613745B1 (fr)	2021-09-01
CN108349978A (zh)	2018-07-31

Publication	Publication Date	Title
IL274066A (en)	2020-06-30	Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
IL262964B (en)	2021-06-30	Preparation of (s)-n-(5-((r)-2-(5,2-difluorophenyl)pyrrolidine-1-yl)pyrazolo[5,1-a]pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide and their salts
IL262003A (en)	2018-10-31	Liquid formulations of (s)-n-(5-((r)-2-(5,2-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[5,1-a]pyrimidin-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide
SI3699181T1 (sl)	2023-06-30	Kristalinična oblika(s)-n-(5-((r)-2-(2,5-difluorofenil)- pirolidin-1-il)-pirazolo(1,5-a)pirimidin-3-il)-3-hidroksipirolidin-1 -karboksamid hidrogen sulfata
PT3041475T (pt)	2025-01-07	Compostos baseados em pirazolo[1,5-a]pirimidina, composições compreendendo-os e métodos da sua utilização